BDX

Becton Dickinson andD

NYSE / Health Care Equipment & Services

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+1

B+

Bull case

30%

Probability

Target price

$180.00

+24.6% vs current

Most likely

Base case

45%

Probability

Target price

$166.00

+14.9% vs current

B-

Bear case

25%

Probability

Target price

$138.00

-4.5% vs current

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

Near-term headline tone turned positive on the May 7 print because BD beat on adjusted EPS, modestly exceeded trusted revenue expectations, and raised full-year adjusted EPS guidance. Trusted market coverage also described a positive immediate reaction, including pre-market gains of roughly 2.5%, but this remains an early T+1 read and analyst revision breadth was still thin, so the setup is better described as a constructive monitoring reset than a fully confirmed rerating. Social coverage was not provided in the packet.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators

Impact

tentative

Confidence

AI events

2026-05-08eventQ2 beat with higher FY26 adjusted EPS guideMedium impact

BD reported fiscal Q2 2026 revenue of $4.714B, adjusted EPS of $2.90, reaffirmed low-single-digit FX-neutral revenue growth, and raised FY26 adjusted EPS guidance to $12.52-$12.72 from $12.35-$12.65, while management said revenue, margins and EPS were ahead of expectations [#8-K-2026-05-07].

2026-08-06catalystCapital allocation and deleveraging improve the earnings bridgeMedium impact

BD executed a $2.0B ASR and retired $2.1B of debt in the quarter; the March 31 balance sheet also showed long-term debt down to $13.779B from $16.745B at fiscal year-end, which helps the near-term capital-allocation narrative if operating execution holds [#8-K-2026-05-07] [#10-Q-2026-05-07].

2026-09-30catalystGrowth-platform launches and regulatory milestones support H2 mixMedium impact

The May 7 earnings release highlighted the commercial launch of CentroVena One, European launches for Pyxis Pro and Incada, HemoSphere Stream expansion, CE Marks for Revello and Liverty, and FDA 510(k) clearance for Surgiphor, which can support mix and procedure-linked growth if adoption converts through fiscal 2026 [#8-K-2026-05-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology